代写论文：医学出版界的肮脏小秘密，现在变得更大了。
Ghostwriting: the dirty little secret of medical publishing that just got bigger.
出版信息
PLoS Med. 2009 Sep;6(9):e1000156. doi: 10.1371/journal.pmed.1000156. Epub 2009 Sep 8.
Abstract
In an academic_editorial highlighting the 1,500 documents made public after 's intervention in a court case, the academic_editors call for strong action to be taken to eradicate this practice.
摘要
在一篇学术社论中，重点介绍了在“干预一起法庭案件”之后公开的 1500 份文件，学术编辑呼吁采取强有力的行动来根除这种做法。
相似文献
1
Ghostwriting: the dirty little secret of medical publishing that just got bigger.代写论文：医学出版界的肮脏小秘密，现在变得更大了。
PLoS Med. 2009 Sep;6(9):e1000156. doi: 10.1371/journal.pmed.1000156. Epub 2009 Sep 8.
2
Ghostwriting in medical literature.医学文献中的代笔问题。
Int J Occup Environ Health. 2011 Apr-Jun;17(2):168-77.
3
Commentary: What's wrong with ghostwriting?评论：代笔写作有什么问题？
Bioethics. 2010 Jul;24(6):284-6. doi: 10.1111/j.1467-8519.2010.01828.x. Epub 2010 May 17.
4
[Ghostwriting].（代笔）
Tidsskr Nor Laegeforen. 2008 May 1;128(9):1039.
5
Authorship policy.作者政策。
Am J Ophthalmol. 2009 Jan;147(1):184; author reply 184-5. doi: 10.1016/j.ajo.2008.09.031.
6
Profits and plagiarism: the case of medical ghostwriting.利润与剽窃：医学代写的案例。
Bioethics. 2010 Jul;24(6):267-72. doi: 10.1111/j.1467-8519.2008.00705.x. Epub 2009 Feb 16.
7
The sins of ghostwriting.代笔的罪过。
Am J Ther. 2008 Jul-Aug;15(4):297-8. doi: 10.1097/MJT.0b013e318180f387.
8
Corporate versus public interests: community responsibility to defend scientific integrity.企业利益与公众利益：捍卫科学诚信的社会责任
Int J Occup Environ Health. 2011 Apr-Jun;17(2):181-5.
9
How to ensure our readers' trust: the proper attribution of authors and contributors.如何确保读者的信任：作者和贡献者的恰当署名
Am J Ophthalmol. 2008 Sep;146(3):337-40. doi: 10.1016/j.ajo.2008.06.007.
10
Ghostwriting: stringent disclosure policies take aim at authorship abuses.代笔问题：严格的披露政策旨在打击署名滥用行为。
Aesthet Surg J. 2010 Mar;30(2):265-6. doi: 10.1177/1090820X10370167.
引用本文的文献
1
How big is the medical writing industry? Why it matters.医学写作行业规模有多大？为何它很重要。
Health Promot Int. 2025 Sep 3;40(5). doi: 10.1093/heapro/daaf146.
2
What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review.科学文献从制药行业的公司内部文件中学到了什么？一项范围综述。
Cochrane Evid Synth Methods. 2023 Apr 27;1(3):e12011. doi: 10.1002/cesm.12011. eCollection 2023 May.
3
Assessment of clinical trial protocols for pathology content using the SPIRIT-Path guidelines highlights areas for improvement.使用 SPIRIT-Path 指南评估包含病理学内容的临床试验方案，突出了需要改进的领域。
J Pathol Clin Res. 2022 Sep;8(5):411-421. doi: 10.1002/cjp2.274. Epub 2022 May 31.
4
Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials.通过合并来隐藏负面试验：对 FDA 注册抗抑郁药试验中合并试验发表偏倚的二次分析。
Psychol Med. 2019 Sep;49(12):2020-2026. doi: 10.1017/S0033291718002805. Epub 2018 Sep 28.
5
Publication planning: promoting an ethics of transparency and integrity in biomedical research.出版规划：促进生物医学研究中的透明度和诚信伦理
Int J Clin Pract. 2015 Sep;69(9):915-21. doi: 10.1111/ijcp.12708.
6
Writers Blocked: On the Wrongs of Research Co-authorship and Some Possible Strategies for Improvement.写作受阻：论研究共同署名的问题及一些可能的改进策略。
Sci Eng Ethics. 2015 Oct;21(5):1315-29. doi: 10.1007/s11948-014-9606-0. Epub 2014 Oct 28.
7
Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literature.关于医学文献中代笔行为发生率的主要和次要报告的系统评价。
BMJ Open. 2014 Jul 14;4(7):e004777. doi: 10.1136/bmjopen-2013-004777.
8
Challenging medical ghostwriting in US courts.在美国法庭上挑战医疗 ghostwriting。
PLoS Med. 2012 Jan;9(1):e1001163. doi: 10.1371/journal.pmed.1001163. Epub 2012 Jan 24.
9
Promoting transparency in pharmaceutical industry-sponsored research.促进制药行业赞助研究的透明度。
Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.
10
Ghostwriting revisited: new perspectives but few solutions in sight.代笔问题再探讨：新视角，仍无解。
PLoS Med. 2011 Aug;8(8):e1001084. doi: 10.1371/journal.pmed.1001084. Epub 2011 Aug 30.
本文引用的文献
1
An unbiased scientific record should be everyone's agenda.一份公正的科学记录应该是每个人的议程。
PLoS Med. 2009 Feb 24;6(2):e1000038. doi: 10.1371/journal.pmed.1000038.
2
What should be done to tackle ghostwriting in the medical literature?应该采取什么措施来应对医学文献中的代笔问题？
PLoS Med. 2009 Feb 3;6(2):e23. doi: 10.1371/journal.pmed.1000023.
3
Impugning the integrity of medical science: the adverse effects of industry influence.质疑医学科学的诚信：行业影响的不良后果。
JAMA. 2008 Apr 16;299(15):1833-5. doi: 10.1001/jama.299.15.1833.
4
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.与罗非昔布相关出版物中的客座作者身份和代笔行为：以罗非昔布诉讼中的行业文件为例
JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.
5
Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?幽灵作者现象：医药行业在幕后对医学文献的影响究竟有多大？
PLoS Med. 2007 Sep;4(9):e286. doi: 10.1371/journal.pmed.0040286.
6
Authors, ghosts, damned lies, and statisticians.作者、幽灵、该死的谎言与统计学家。
PLoS Med. 2007 Jan;4(1):e34. doi: 10.1371/journal.pmed.0040034.
7
Ghost authorship in industry-initiated randomised trials.行业发起的随机试验中的代笔问题。
PLoS Med. 2007 Jan;4(1):e19. doi: 10.1371/journal.pmed.0040019.
8
Ghost writing initiated by commercial companies.由商业公司发起的代笔行为。
J Gen Intern Med. 2005 Jun;20(6):549. doi: 10.1111/j.1525-1497.2005.41015.x.
9
10
Good publication practice for pharmaceutical companies.制药公司良好出版规范。
Curr Med Res Opin. 2003;19(3):149-54. doi: 10.1185/030079903125001767.
Zotero 插件